207 related articles for article (PubMed ID: 8961049)
1. Effect of RO 23-9424, cefotaxime and fleroxacin on functions of human polymorphonuclear cells and cytokine production by human monocytes.
Matera G; Berlinghieri MC; Foti F; Barreca GS; Focà A
J Antimicrob Chemother; 1996 Nov; 38(5):799-807. PubMed ID: 8961049
[TBL] [Abstract][Full Text] [Related]
2. Anti-Brucella activity of Ro 23-9424, a dual-action antibacterial.
Qadri SM; Ueno Y; Ayub A
Chemotherapy; 1993; 39(6):386-9. PubMed ID: 8222864
[TBL] [Abstract][Full Text] [Related]
3. The effect of TNF-alpha, PMA, and LPS on plasma and cell-associated IL-8 in human leukocytes.
Lund T; Østerud B
Thromb Res; 2004; 113(1):75-83. PubMed ID: 15081568
[TBL] [Abstract][Full Text] [Related]
4. Mode of action of the dual-action cephalosporin Ro 23-9424.
Georgopapadakou NH; Bertasso A; Chan KK; Chapman JS; Cleeland R; Cummings LM; Dix BA; Keith DD
Antimicrob Agents Chemother; 1989 Jul; 33(7):1067-71. PubMed ID: 2675755
[TBL] [Abstract][Full Text] [Related]
5. Low-level resistance to the cephalosporin 3'-quinolone ester Ro 23-9424 in Escherichia coli.
Chapman JS; Bertasso A; Cummings LM; Georgopapadakou NH
Antimicrob Agents Chemother; 1995 Feb; 39(2):564-6. PubMed ID: 7726536
[TBL] [Abstract][Full Text] [Related]
6. Modulation of proinflammatory cytokine release from human polymorphonuclear leukocytes by gamma interferon.
Meda L; Gasperini S; Ceska M; Cassatella MA
Cell Immunol; 1994 Sep; 157(2):448-61. PubMed ID: 8069926
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of a dual-action antibacterial agent, Ro 23-9424, and comparative agents.
Beskid G; Fallat V; Lipschitz ER; McGarry DH; Cleeland R; Chan K; Keith DD; Unowsky J
Antimicrob Agents Chemother; 1989 Jul; 33(7):1072-7. PubMed ID: 2782857
[TBL] [Abstract][Full Text] [Related]
8. RO 23-9424, a new cephalosporin 3'-quinolone: in-vitro antimicrobial activity and tentative disc diffusion interpretive criteria.
Pfaller MA; Barry AL; Fuchs PC
J Antimicrob Chemother; 1993 Jan; 31(1):81-8. PubMed ID: 8444677
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.
Spangler SK; Jacobs MR; Pankuch GA; Appelbaum PC
J Antimicrob Chemother; 1993 Feb; 31(2):273-80. PubMed ID: 8463172
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of two new oral cephalosporins, cefixime and cefdinir (CI 983), on human peripheral mononuclear and polymorphonuclear leukocyte functions.
Fietta A; Merlini C; Gialdroni Grassi G
Chemotherapy; 1994; 40(5):317-23. PubMed ID: 7956455
[TBL] [Abstract][Full Text] [Related]
11. In vivo evaluation of a dual-action antibacterial, Ro 23-9424, compared to cefotaxime and fleroxacin.
Beskid G; Siebelist J; McGarry CM; Cleeland R; Chan K; Keith DD
Chemotherapy; 1990; 36(2):109-16. PubMed ID: 2107064
[TBL] [Abstract][Full Text] [Related]
12. IFN-gamma and LPS overcome glucocorticoid inhibition of priming for superoxide release in human monocytes. Evidence that secretion of IL-1 and tumor necrosis factor-alpha is not essential for monocyte priming.
Szefler SJ; Norton CE; Ball B; Gross JM; Aida Y; Pabst MJ
J Immunol; 1989 Jun; 142(11):3985-92. PubMed ID: 2541203
[TBL] [Abstract][Full Text] [Related]
13. Cefodizime modulates in vitro tumor necrosis factor-alpha, interleukin-6 and interleukin-8 release from human peripheral monocytes.
Meloni F; Ballabio P; Bianchi L; Grassi FA; Gialdroni Grassi GG
Chemotherapy; 1995; 41(4):289-95. PubMed ID: 7555210
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of Ro 23-9424, a dual-acting cephalosporin-quinolone antimicrobial agent.
Qadri SM; Ueno Y; Saldin H; Cunha BA
J Clin Pharmacol; 1993 Oct; 33(10):923-8. PubMed ID: 8227462
[TBL] [Abstract][Full Text] [Related]
15. Effect of glucose concentration, osmolality, and sterilization process of peritoneal dialysis fluids on cytokine production by peripheral blood mononuclear cells and polymorphonuclear cell functions in vitro.
Cendoroglo M; Sundaram S; Jaber BL; Pereira BJ
Am J Kidney Dis; 1998 Feb; 31(2):273-82. PubMed ID: 9469498
[TBL] [Abstract][Full Text] [Related]
16. Effects of cefotaxime and cefodizime on human granulocyte functions in vitro.
Labro MT; Babin-Chevaye C; Hakim J
J Antimicrob Chemother; 1986 Aug; 18(2):233-7. PubMed ID: 3019985
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of Ro 23-9424 against clinical isolates of Legionella species.
Edelstein PH; Edelstein MA
Antimicrob Agents Chemother; 1992 Nov; 36(11):2559-61. PubMed ID: 1489206
[TBL] [Abstract][Full Text] [Related]
18. Induction of tumor necrosis factor-alpha by cefodizime in U-937 cells.
Guerra-Infante FM; Zamora-Ruíz A; López-Hurtado M; Flores-Medina S
Rev Invest Clin; 2001; 53(4):335-9. PubMed ID: 11599481
[TBL] [Abstract][Full Text] [Related]
19. Effect of cefotaxime on cytokine production in newborns and adults in vitro.
Bessler H; Gurary N; Aloni D; Vishne TH; Sirota L
Biomed Pharmacother; 2000 Aug; 54(7):410-4. PubMed ID: 10989981
[TBL] [Abstract][Full Text] [Related]
20. Glutamine and alanine-induced differential expression of intracellular IL-6, IL-8, and TNF-α in LPS-stimulated monocytes in human whole-blood.
Raspé C; Czeslick E; Weimann A; Schinke C; Leimert A; Kellner P; Simm A; Bucher M; Sablotzki A
Cytokine; 2013 Apr; 62(1):52-7. PubMed ID: 23498057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
